CJC-1295 (no DAC) / Mod GRF 1-29

Published · Researched 2026-09-21

Research documentation only. Dated 2026-09-20. Part of the GH-secretagogues deep-research track.

Overview

CJC-1295 (no DAC) — sold under the interchangeable names Modified GRF 1-29 and Mod GRF(1-29) — is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH) with four amino-acid substitutions that confer resistance to enzymatic (DPP-IV) breakdown. Community sources agree these are all the same molecule: the "no DAC" label exists to distinguish it from the Drug Affinity Complex-conjugated version (see cjc-1295-dac). Original development traces to ConjuChem Biotechnologies in the early 2000s; the no-DAC variant has no active clinical development pathway and is sold strictly as a research chemical for research reference, not human use. As of 2026 it is not FDA- or EMA-approved for any indication. Its distinguishing pharmacokinetic trait is a short half-life (~30 minutes), producing brief, pulsatile GH pulses that more closely mirror the body's natural rhythm — the reason community and educator consensus has shifted toward it and away from the DAC version.

Social standing

This is half of the dominant community stack. CJC-1295 no DAC + Ipamorelin is the most discussed peptide pairing across every platform in the evidence set (bodybuilding and anti-aging/longevity audiences alike). Standard community-reported dosing is 100 mcg of each, 1–3x daily, typically administered fasted/bedtime to align with nocturnal GH pulses; several FB-group threads describe fasting windows of 90–120 minutes before and ~30 minutes after.

Viral moment: Biohacker Bryan Johnson's June 16, 2026 Instagram reel ("some friendly advice on peptides") shows him holding vials of Tirzepatide and CJC-1295 with DAC, then explaining he stopped after two DAC doses. His self-reported biomarkers after the two doses: REM sleep down 23%, fasted blood sugar up 20%, cortisol up 12%, insulin resistance up 50%, c-peptide up 53% (self-reported n=1, not a clinical result). The comments are dominated by users saying no-DAC plus Ipamorelin is the standard pulsatile protocol and the DAC choice was the mistake — this reel effectively became a mass education moment for the no-DAC/Ipa protocol.

Instagram (owner + educator content): Coach Chris Lane's Aug 24, 2026 reel promotes a CJC-1295-no-DAC/Ipamorelin blend with the football analogy "CJC calls the play, Ipamorelin triggers the snap," and drew questions about timing and appetite effects. Dr. Pat Taylor (Live Vital/Belle Health) posted a Sept 11, 2026 carousel calling CJC-1295 + Ipamorelin "THE MOST POPULAR STACK YOU HAVEN'T HEARD OF." The RIPD.FIT account's Jan 14, 2026 stack graphic lists "CJC-1295 NO DAC (100MCG)-3X DAILY" alongside Ipamorelin (100MCG 3x daily); commenters call it clean and educational, with repeated phrases like "Science > guessing." KPC Wellness's Sept 4, 2026 GHRH+GHRP ranking places Mod GRF(1-29) mid-pack, noting evidence and selectivity matter more than potency. Caroline Labouchere (54-year-old model/influencer) announced July 2, 2026 she started a CJC-1295 + Ipamorelin injectable regimen, and a Sept 2, 2026 post by @htxpeptides (over-50 user) reports improved sleep, recovery, and body composition.

FB Groups: John Jones (June 6, 2026) asked about stacking CJC-1295 with Ipamorelin without DAC; commenters reported improved sleep, faster recovery, harder muscles, modest fat loss within weeks, and shared starting doses around 200 mcg, alongside sourcing offers. A Feb 4, 2026 timing thread in the same community reached consensus against pre/post-workout use, favoring nighttime fasted administration. Rita James (July 23, 2026) reported peer-affirmed positive sleep and recomposition outcomes. Shawna Staggs (Sept 2, 2026) reported sluggishness on a 5-units (0.5 mg) dose; commenters said 500 mcg is excessive versus typical 100–300 mcg ranges and urged lower doses and fasted nighttime timing.

Main praise: better sleep quality and depth, faster recovery, modest fat loss/visceral fat reduction, improved skin, and lab-verified IGF-1 increases (self-reported). Main complaints: the "CJC flush" (flushing, warmth, occasional diarrhea after first injections — widely memed, e.g. the Homelander "first-time CJC flush panic" meme, Sept 2025); water retention early on (reported as correcting within weeks); headaches; sluggishness or hunger when doses are set too high; insomnia in a minority; and cost complaints about multi-month stacks.

Scam-warning Meta finding (from shared pulse): The small FB group "Peptide Community 101" is largely admin-run supplier spam ("verified supplier join the WhatsApp"); FB Marketplace returned zero listings for ipamorelin/tesamorelin/MK-677 — sales happen off-platform. Many comment threads on CJC/Ipa posts are flooded with supplier spam (Napsgear, PepSource, Telegram groups, DM price lists).

Social validation — Tier 1

FB Groups + Instagram owner content + Threads coverage all present.

Key specs table

Property Value
Synonyms Mod GRF 1-29, Modified GRF 1-29, CJC-1295 without DAC
Class GHRH analog (29-aa GHRH 1-29 analog, 4 substitutions, DPP-IV resistant)
Mechanism Binds GHRH receptor on pituitary somatotrophs → cAMP pathway → pulsatile GH release
Half-life ~30 minutes (community/educator consensus; no albumin binding)
Route Subcutaneous injection (high SC bioavailability, negligible oral)
Community-reported dosing 100–300 mcg 1–3x daily, commonly bedtime fasted (community-reported; NOT medical guidance)
Molecular weight ~3367.94 g/mol (C152H252N44O42)
CAS 863288-34-0
GH profile Pulsatile, physiological; IGF-1 elevation reported in literature without pituitary rhythm suppression
FDA/EMA status Not approved

Sources: vendor spec sheets (Atomix Research: CAS 863288-34-0, MW ~3367.9; Profound Aminos; ARL spec card visible in product photo, observation 2026-09-20); mechanism detail from GenDarwin Research educational carousel (Aug 2026) and Josh Holyfield dual-receptor explainer (Aug 9, 2026); half-life consensus from biohacking-unlocked GitHub guide and peptide dosing protocol sites (web check 2026-09-20).

Pricing

  • MSRP: none — research chemical, no branded human pharmaceutical product exists.
  • Research-chem street: CJC-1295/Ipamorelin blend 5 mg/5 mg vials: $52.00 (Guardian Labs), $59.99 (Atomix Research), $60.00 (Polaris Peptides), $69.99 (Soma Chems) — observations 2026-09-20. Single-compound benchmark (PeptidePub 2026 catalog data via Medium, captured 2026-07-14): CJC-1295 10 mg list $73, ~$36.50 effective after code; Ipamorelin 5 mg list $44, ~$22 effective. A Feb 2026 FB-group thread cited community costs of $13–$180 per 10 mg (wide vendor spread, community-reported).
  • Compounded/clinic: Holistic Health and Medical (Miami Lakes) sells "CJC-1295 + Ipamorelin" with third-party COAs (scannable QR) per its Aug–Sep 2026 promotional reels; clinic price not observed — UNVERIFIED. Broader clinic pricing for this stack not captured in sources (UNVERIFIED).
  • Facebook Marketplace range: no listings observed 2026-09-20 (zero listings for related peptides; sales occur off-platform per shared pulse).

What's included / what's needed

Vial: white lyophilized powder (commonly 5 mg or 10 mg of CJC-1295 no DAC; blends include 5 mg Ipamorelin). What's needed for laboratory use: bacteriostatic water for reconstitution, sterile syringes/vials and disinfecting supplies; refrigerated storage after reconstitution (stable up to ~30 days per vendor guidance). No usage protocol is documented here — community dosing above is reported evidence only, not instructions.

Support reality

  • Warranty: n/a for research chemicals (no consumer product).
  • Vendor COA practices: range from HPLC/MS per-batch COAs with third-party labs (some published, e.g., Freedom Diagnostics reports on Peptide Foundry; some vendors note net peptide content vs label) to vendors with no verifiable testing. Community reports vendor reliability is uneven; counterfeit/low-purity vials are a recurring complaint in group threads. No vendor endorsements are made here.
  • Clinic support: clinics offering the stack (e.g., Holistic Health and Medical, Miami Lakes) bundle bloodwork and provider monitoring; quality and pricing vary widely and are UNVERIFIED beyond their promotional claims.

Regulatory & safety status

Research chemical not for human use. Not FDA- or EMA-approved for any indication; not a dietary supplement; ConjuChem discontinued clinical development of the CJC-1295 program (with-DAC) in 2008 (educator source; see dac file). WADA: prohibited in sports (S2 — peptide hormones, growth factors, related substances and mimetics). Known safety signals: from literature/educator summaries, acute effects include injection-site reactions and mild fluid retention; community reports include flushing ("CJC flush"), headaches, water retention, occasional GI upset, and hunger/sluggishness at higher community doses. Note the DAC insulin-resistance signal from the Bryan Johnson self-experiment (fasted glucose +20%, insulin resistance +50% after 2 DAC doses, self-reported n=1) — applies to the DAC form, and is precisely why community guidance favors the short-acting no-DAC form. No long-term human safety data exists for the no-DAC research-chem channel.

Community verdict

CJC-1295 no DAC plus Ipamorelin is the community's default GH-secretagogue stack for sleep, recovery, and body recomposition, with strong anecdotal reporting and one of the most developed crowdsourced dosing consensuses in the peptide scene. Enthusiasm is real but evidence is anecdotal: no long-term safety data, heavy vendor spam noise around sourcing, and dose-related side effects (flushing, water retention) are the main complaints.

Image log

  • hero: present — cjc-1295-no-dac-hero.jpg (Moon Peptides CJC-1295 (No DAC) 5MG product shot). Source: image-search result page (Shopify storefront), observation 2026-09-20.
  • side: present — cjc-1295-no-dac-side.jpg (31-32 Peptides CJC-1295 (No DAC) 10mg product shot). Source: http://31-32peptides.com/products, observation 2026-09-20.
  • rear: missing — no rear-label view found among candidates.
  • top: missing — no cap/top-down view found.
  • detail: present — cjc-1295-no-dac-detail.jpg (ARL spec card: "CJC-1295 No DAC, Mod GRF 1-29, CAS 863288-34-0, M.W. 3367.94 g/mol, 99% HPLC, RUO" alongside vial). Source: https://floridapeptideslab.com/products/nad, observation 2026-09-20.
  • inuse: missing — no owner-use photo found.
  • scale: missing — no scale/reference object shot found.
  • box: present — cjc-1295-no-dac-box.jpg (PEPTO MED 5mg retail box + vial, "CJC-1295 NO DAC / PURE PEPTIDES / FOR RESEARCH USE ONLY"). Source: https://gemkibo.pl/genkibo-home-page-clone/, observation 2026-09-20.

Open questions / UNVERIFIED

  • Whether Ipamorelin truly desensitizes (~45% GH-output drop by week 16, 4-week reset) while CJC/tesamorelin do not — creator-cited (IG educator, May 4 2026); verify before stating as fact.
  • Exact molecular identity of what gray-market vendors label "CJC-1295 no DAC" vs "Mod GRF 1-29" batch to batch — community treats them as the same molecule; independent verification per batch unavailable.
  • Clinic pricing for the CJC-1295 + Ipamorelin stack (e.g., Holistic Health and Medical) — not observed; UNVERIFIED.
  • Community efficacy claims (IGF-1 increases, visceral fat loss, skin/hair improvements) — anecdotal, no controlled human data in this channel.
  • Bryan Johnson's biomarker numbers — self-reported n=1 from his own reel graphics; not clinical evidence.

Not medical advice. This file is research documentation only; nothing here is a recommendation to use any compound.

CJC-1295 (no DAC) / Mod GRF 1-29 — box view
box view Original vendor page URL not recorded in research dossier
CJC-1295 (no DAC) / Mod GRF 1-29 — detail view
detail view Original vendor page URL not recorded in research dossier
CJC-1295 (no DAC) / Mod GRF 1-29 — hero view
hero view Original vendor page URL not recorded in research dossier
CJC-1295 (no DAC) / Mod GRF 1-29 — side view
side view Original vendor page URL not recorded in research dossier

Sources